Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
Lynx1 Capital Management L.P., a ten percent owner of Passage Bio, Inc. (NASDAQ:PASG), has increased its stake in the company through a series of purchases. According to a Form 4 filing with the Securities and Exchange Commission, the firm acquired a total of 128,848 shares of Passage Bio common stock between July 22 and July 24. The insider buying comes as the stock trades significantly below its 52-week high, having declined over 50% in the past six months. According to InvestingPro analysis, the company currently appears undervalued.
The purchases were executed at weighted average prices ranging from $5.4361 to $5.7408 per share, resulting in a total transaction value of approximately $733,825.
Specifically, on July 22, Lynx1 Capital bought 13,123 shares in multiple transactions at prices ranging from $5.33 to $5.475. On July 23, the firm acquired 49,302 shares at prices between $5.675 and $5.8. The buying spree concluded on July 24 with the purchase of 66,423 shares at prices ranging from $5.535 to $5.9.
Following these transactions, Lynx1 Capital now holds 591,696 shares of Passage Bio.
In other recent news, Passage Bio announced a 1-for-20 reverse stock split, which took effect on July 14, 2025. This move aims to help the company meet Nasdaq’s minimum bid price requirement of $1.00 per share. Passage Bio continues to trade under its existing symbol but with a new CUSIP number. Additionally, the company reported updated interim data from its Phase 1/2 upliFT-D clinical trial for PBFT02, a gene therapy targeting frontotemporal dementia (FTD). The data indicated that patients receiving the higher dose maintained elevated cerebrospinal fluid progranulin levels for 18 months post-treatment. The first patient treated with a lower dose showed significant increases in progranulin levels at one month. These developments are part of Passage Bio’s ongoing efforts to advance its therapeutic pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.